NYSE - Delayed Quote USD

AbbVie Inc. (ABBV)

159.62 -7.67 (-4.58%)
At close: April 26 at 4:00 PM EDT
160.00 +0.38 (+0.24%)
After hours: April 26 at 7:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
54,318,000.00
54,318,000.00
58,054,000.00
56,197,000.00
45,804,000.00
Cost of Revenue
20,415,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
Gross Profit
33,903,000.00
33,903,000.00
40,640,000.00
38,751,000.00
30,417,000.00
Operating Expense
20,368,000.00
20,368,000.00
21,826,000.00
19,703,000.00
17,678,000.00
Operating Income
13,535,000.00
13,535,000.00
18,814,000.00
19,048,000.00
12,739,000.00
Net Non Operating Interest Income Expense
-1,684,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
Other Income Expense
-5,601,000.00
-5,601,000.00
-3,293,000.00
-3,675,000.00
-7,061,000.00
Pretax Income
6,250,000.00
6,250,000.00
13,477,000.00
12,989,000.00
3,398,000.00
Tax Provision
1,377,000.00
1,377,000.00
1,632,000.00
1,440,000.00
-1,224,000.00
Net Income Common Stockholders
4,863,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
Diluted NI Available to Com Stockholders
4,863,000.00
4,820,000.00
11,782,000.00
11,468,000.00
4,556,000.00
Basic EPS
2.73
2.75
6.65
6.48
2.73
Diluted EPS
2.72
2.72
6.63
6.45
2.72
Basic Average Shares
1,768,000.00
1,765,940.73
1,771,000.00
1,770,000.00
1,667,000.00
Diluted Average Shares
1,773,000.00
1,773,000.00
1,778,000.00
1,777,000.00
1,673,000.00
Total Operating Income as Reported
12,757,000.00
12,757,000.00
18,117,000.00
17,924,000.00
11,363,000.00
Total Expenses
40,783,000.00
40,783,000.00
39,240,000.00
37,149,000.00
33,065,000.00
Net Income from Continuing & Discontinued Operation
4,863,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
Normalized Income
5,583,720.00
5,583,720.00
12,578,755.00
12,586,575.00
5,672,310.00
Interest Income
540,000.00
540,000.00
186,000.00
39,000.00
174,000.00
Interest Expense
2,224,000.00
2,224,000.00
2,230,000.00
2,423,000.00
2,454,000.00
Net Interest Income
-1,684,000.00
-1,684,000.00
-2,044,000.00
-2,384,000.00
-2,280,000.00
EBIT
13,535,000.00
8,474,000.00
15,707,000.00
15,412,000.00
5,852,000.00
EBITDA
13,535,000.00
17,172,000.00
24,174,000.00
23,933,000.00
12,323,000.00
Reconciled Cost of Revenue
20,415,000.00
20,415,000.00
17,414,000.00
17,446,000.00
15,387,000.00
Reconciled Depreciation
8,698,000.00
8,698,000.00
8,467,000.00
8,521,000.00
6,471,000.00
Net Income from Continuing Operation Net Minority Interest
4,863,000.00
4,863,000.00
11,836,000.00
11,542,000.00
4,616,000.00
Total Unusual Items Excluding Goodwill
-924,000.00
-924,000.00
-845,000.00
-1,175,000.00
-1,447,000.00
Total Unusual Items
-924,000.00
-924,000.00
-845,000.00
-1,175,000.00
-1,447,000.00
Normalized EBITDA
14,459,000.00
18,096,000.00
25,019,000.00
25,108,000.00
13,770,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-203,280.00
-203,280.00
-102,245.00
-130,425.00
-390,690.00
12/31/2020 - 1/2/2013

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BMY Bristol-Myers Squibb Company
44.85
+0.34%
 
MRK Merck & Co., Inc.
131.20
+0.37%
 
PFE Pfizer Inc.
25.40
+0.55%
 
JNJ Johnson & Johnson
146.14
-0.46%
 
LLY Eli Lilly and Company
733.51
+1.19%
 
GILD Gilead Sciences, Inc.
65.42
+0.23%
 
BIIB Biogen Inc.
208.90
+3.18%
 
AZN AstraZeneca PLC
75.17
+0.19%
 
AMGN Amgen Inc.
269.98
+0.22%
 
NVS Novartis AG
97.44
-1.64%